2009
|
Nienaber et al.
(INSTEAD)
|
Clinical trial
|
Total: 140
TEVAR with OMT: 72
OMT only: 68
|
No significant difference in all-cause mortality at 2 years between
TEVAR with OMT and OMT only groups (P=0.15).
|
2013
|
Nienaber et al.
(INSTEAD-XL)
|
Clinical trial
|
Total: 140
TEVAR with OMT: 72
OMT only: 68
|
No significant difference in all-cause mortality during follow-up period
(2-5 years) between TEVAR with OMT (11.1%) and OMT only (19.3%) groups
(P=0.13).
|
2014
|
Brunkwall et al.
(1-year Results of the ADSORB Trial)
|
Clinical trial
|
Total: 61
TEVAR with BMT: 30
BMT only: 31
|
One death due to cardiac arrest in TEVAR with BMT group recorded.
|
2016
|
Qin et al.
|
Observational study
|
Total: 338
TEVAR with OMT: 184
OMT only: 154
|
Total of 50 late (>30 days) deaths observed (27
aortic-related; 18 unrelated to dissection; 5 unknown).
All-cause mortality significantly lower for TEVAR with OMT group
(P=0.01).
|
2017
|
Enezate et al.
|
Systematic review and meta-analysis
|
6 studies
Total: 1960
|
No significant difference between BMT and TEVAR all-cause mortality in
short-term (30 days; P=0.15), intermediate (1 year; P=0.96) and mid-term
(2-5 years; P=0.75).
|
2018
|
Tjaden Jr. et al.
|
Observational study
|
Total: 264
Acute TBAD: 170 (un-TBAD 69; co-TBAD 101)
Chronic TBAD: 94 (un-TBAD 40; co-TBAD 54)
|
Overall all-cause mortality is 12.5% in follow-up period (mean 26
months).
Significantly lower all-cause mortality rate for acute TBAD (P=0.02).
Multivariate analysis shows overall survival significantly higher for
acute un-TBAD (93%) compared to other subtypes (83%) at 2 years
(P<0.05).
|
2018
|
Iannuzzi et al.
|
Observational study
|
Total: 9165
OMT: 95%
TEVAR: 2.9%
Open repair: 2%
|
1-year survivals (OMT: 84%; TEVAR: 85%; Open repair: 76%) and 5-year
survivals (OMT: 60%; TEVAR: 76%; Open repair: 67%)
(P<0.01).
Risk-adjusted multivariable analysis shows significantly improved
survival for TEVAR compared with OMT (P<0.01) and no
significant difference between OMT and open repair
(P<0.01).
|
2020
|
Hossack et al.
|
Systematic review and meta-analysis
|
6 studies
Total: 14706
(TEVAR: 1066)
|
Significantly lower risk of all-cause mortality (P<0.001) and
aorta related mortality (P=0.001) for TEVAR when compared to BMT.
|
2020
|
Torrent et al.
|
Observational study
|
Total: 688
Acute un-TBAD: 446
Subacute un-TBAD: 242
|
1-year mortality for acute and subacute un-TBAD patients undergoing
TEVAR (13.3% and 8.2% respectively; P=0.129).
After propensity score matching 1- year mortality for acute and subacute
patients (12.4% and 9.9% respectively; P=0.5).
|
2020
|
Bi et al.
|
Observational study
|
Total: 53
Acute TBAD with TEVAR: 22
Subacute TBAD with TEVAR: 18
Non-operative: 13
|
3-year survival rates for acute TBAD with TEVAR, subacute TBAD with
TEVAR, non-operative groups (95.5%, 100%, 85.7% respectively).
|
2021
|
Spinelli et al.
|
Observational study
|
Total: 172
Acute un-TBAD with TEVAR: 70
Acute co-TBAD with TEVAR: 102
|
No significant difference in overall survival between co-TBAD and
un-TBAD patients at 1 year (88.8%±11.2% versus 96.8%±3.1%) and 3
years (79.1%±20.8% vs 90.4% ±9.5%), (P=0.138).
|
2021
|
Xie et al.
|
Observational study
|
Total: 267
Acute un-TBAD: 130
Subacute un-TBAD: 137
|
Cumulative survival rate from all-cause mortality at 5 years for acute
(94.2%; 95% CI 89.1% - 95.7%) and subacute (88.3%;95% CI 81.5% e
95.7%) groups.
No significant difference in all-cause mortality between the 2 groups
(Log rank P=0.24).
|
2021
|
Xiang et al.
|
Observational study
|
Total: 357
TEVAR: 191
BMT: 166
|
Freedom from all-cause mortality higher in TEVAR group than BMT group at
1 (97.2% versus 94.2%), 3 (96.4% versus 88.5%) and 5 years (91.9%
versus 82.2%) (P=0.028).
|
2021
|
Xiang et al.
|
Observational study
|
Total: 238
Acute with TEVAR: 142
Subacute with TEVAR: 96
|
10 all-cause death in acute group versus 9 in subacute group at 5 years.
Landmark analysis reveals comparable all-cause mortality rates between 2
groups at 1 year (P=0.38) and between 1-5 years (P=0.15).
|